<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868968</url>
  </required_header>
  <id_info>
    <org_study_id>CDFV890A12201</org_study_id>
    <secondary_id>2020-005948-33</secondary_id>
    <nct_id>NCT04868968</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)</brief_title>
  <acronym>DFV890-FCAS</acronym>
  <official_title>An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multiple dose, phase II study to assess safety,&#xD;
      tolerability and clinical efficacy of DFV890 in participants with FCAS.&#xD;
&#xD;
      The study includes a screening period, a treatment period and a follow-up period. At most,&#xD;
      the study will last approximately 4 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">February 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline for white cell count (WCC)</measure>
    <time_frame>At pre-baseline and up to 24 hours post-baseline</time_frame>
    <description>To assess the efficacy of DFV890 in patients with FCAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of safety assessments and adverse events</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>To evaluate the safety and tolerability of DFV890 in patients with FCAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-baseline to post-baseline in Physician global assessment of autoinflammatory disease activity</measure>
    <time_frame>At pre-baseline and up to 24 hours post-baseline</time_frame>
    <description>The Physician global assessment of autoinflammatory disease activity is a questionnaire to be completed by the Investigator. It uses a 5- point rating scale: absent, minimal, mild, moderate, and severe. Lower scores represent better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-baseline to post-baseline in Physician's severity assessment of autoinflammatory disease signs and symptoms</measure>
    <time_frame>At pre-baseline and up to 24 hours post-baseline</time_frame>
    <description>The Physician's severity assessment of autoinflammatory disease signs and symptoms is a questionnaire to be completed by the Investigator. It uses a 5-point rating scale: absent, minimal, mild, moderate, and severe. Lower scores represent better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-baseline to post-baseline in Patient's global assessment of disease activity</measure>
    <time_frame>At pre-baseline and up to 24 hours post-baseline</time_frame>
    <description>Patient's global assessment of disease activity is a questionnaire to be completed by the patient. It uses a 5-point rating scale: absent, minimal, mild, moderate, and severe. The patient will select a rating based on the patient's current disease activity at the time of the assessment. Lower scores represent better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Familial Cold Autoinflammatory Syndrome</condition>
  <arm_group>
    <arm_group_label>DFV890</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFV890</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFV890</intervention_name>
    <description>DFV890</description>
    <arm_group_label>DFV890</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any study-specific assessment is&#xD;
             performed&#xD;
&#xD;
          -  Body mass index within the range of 18-35 kg/m2&#xD;
&#xD;
          -  Patients with a genetic diagnosis of FCAS&#xD;
&#xD;
          -  Patients with a clinical history and investigations consistent with FCAS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants currently being treated with anti-rejection and/or immunomodulatory drugs&#xD;
             and the treatment cannot be discontinued or switched to a different medication&#xD;
&#xD;
          -  Clinically significant, suspected active or chronic bacterial (including Mycobacterium&#xD;
             tuberculosis), viral or fungal infection within 30 days prior to dosing.&#xD;
&#xD;
          -  Patients with innate (e.g. TLR immunodeficiencies, defects in IFN-Î³ signaling) or&#xD;
             acquired immune deficiencies (e.g. AIDS).&#xD;
&#xD;
          -  Presence of human immunodeficiency virus (HIV) infection, hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis B core antibody (anti-HBc), or hepatitis C antibodies at&#xD;
             screening&#xD;
&#xD;
          -  Live vaccines within 4 weeks of dosing&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential unless they are using highly effective methods of&#xD;
             contraception&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Cold Auto-inflammatory Syndrome</keyword>
  <keyword>FCAS</keyword>
  <keyword>DFV890</keyword>
  <keyword>NLRP3 inhibitor, inflammasome inhibition</keyword>
  <keyword>Cryopyrin-associated periodic syndromes</keyword>
  <keyword>CAPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

